Trial Profile
Phase-II, Multicenter, Randomized, Double-Blind, Parallel-Group Trial to Compare the Efficacy and Safety of Sorafenib Plus Pravastatin Against Sorafenib Plus Placebo in Patients With Advanced Hepatocarcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Pravastatin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 19 Sep 2017 Status changed from recruiting to completed.
- 16 Nov 2016 This trial was completed in Spain, according to European Clinical Trials Database.
- 25 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.